

Current Trends and Challenges in University Commercialization

Clustering for 21st Century Prosperity



Ashley J. Stevens
President Elect, AUTM

Executive Director, Technology Transfer
Boston University

February 25, 2010
Washington, DC



Association of University Technology Managers®
Advancing Discoveries for a Better World



Universities and Clusters

2

April 4, 1992

YMPIA & YORK HOW BAD? AUTOS HAGGLE-FREE BUYING YOUR TAXES THIS YEAR AND BEYOND

BusinessWeek


APRIL 06, 1992 JUL 6, 1992 A McGRAW-HILL PUBLICATION \$2.50

INDUSTRIAL POLICY

The very phrase rattles the teeth. It implies bureaucracy. It suggests government will pick winners and losers. Done badly, it would certainly hurt America. But with the cold war over and a global economy taking shape, America needs to shore up its competitiveness.

How? Certainly, by investing in education and infrastructure. But that's not enough. We must recharge the "knowledge base"—the basic science and technology that are the foundation of an advanced industrial society. Perhaps we should call it a growth policy.

PAGE 70



02440


October 19, 1992



HOT SPOTS

AMERICA'S NEW GROWTH REGIONS
ARE BLOSSOMING DESPITE THE SLUMP

AT LEAST 600,000
PEOPLE HOLD
HIGH-TECH JOBS
IN THESE PLACES





Ingredients of a High Tech Cluster

- A major research university
- Quality of life
- Build on local industry
- Cooperation between local university, business and gov't.
- Technology transfer from the university
- Funding sources -- state, VC, angels
- Incubators

Phases of Economic Development

- Start-ups
- New division of major US company
- Foreign companies move in
- Export led growth



The Pharmaceutical Industry in Massachusetts



Pharmaceuticals in Massachusetts

- In 1975, one pharmaceutical company in Massachusetts
 - US HQ of Astra AB
- Two events:
 - Spin-outs from Harvard, MIT, BU
 - Massachusetts Biotechnology Research Park



9



DAINIPPON
SUMITOMO
PHARMA



Bristol-Myers Squibb
Company






Current Trends and Challenges in University Commercialization

10


Invention Disclosures Received




11

Source: AUTM 2008 Licensing Activity Survey unless otherwise noted


US Technology Transfer Employment




US Patent Activity




13




People or Patents – Ratio of Patent Budget to Operating Budget




Technology Transfer Budget as % of Research Budget



Source: Abrams, Leung & Stevens, 2010



Start-Ups Formed



2008 Licensing Activity Survey

Invention Disclosures

New US Patent Applications filed	12,072	60.0%
Licenses Signed	5,132	25.5%
US Patents Issued	3,280	16.3%
Start-Ups formed	595	3.0%
Active Licenses	20,115	



Why Is This So Hard?

- Academic inventions are embryonic
- Average success rate (2008) 25.6%
- Median success rate (2008)
 - All institutions 21.7%
 - More than \$200 million research 22.9%
 - Over 100 disclosures 19.7%
 - MIT (2004-2008) 22.2%
 - Stanford (2004-2008) 23.0%
 - WARF (2004-2008) 34.0%



Why Is This So Hard?

- Should we be more selective?
 - Research Corporation Technologies accepted 228 inventions from 1991-2008
 - ~13/year
 - 29% licensing success rate




Why Is This So Hard?

- Should we invest more to make them less embryonic?
- Translational Research
 - von Liebig (UCSD) and Deshpande (MIT) Centers
 - Philanthropically funded
 - Von Liebig \$10 million
 - Deshpande \$20 million
 - Founded 2001 and 2002

	<u>Von Liebig</u>	<u>Deshpande</u>
Annual Investment	\$1.2 mm	\$1.7 mm
Projects Funded	66	64
Licenses	4 6%	1 2%
Start-Ups	16 24%	1016%
Capital Raised	\$71 mm	\$88.7 mm

Source: Kauffman Foundation, 2008



Financial Performance

<u>Financial Contribution</u>	<u>Number</u>	<u>%</u>
Loss making	68	52.3%
Gross profitable	27	20.8%
Net profitable	14	10.8%
<u>Self sustaining</u>	<u>21</u>	<u>16.2%</u>
Total	130	

Source: Abrams, Leung & Stevens, 2010



Why Such a Difficult Business Model?

- Income is distributed very unevenly
 - A business of a few “big hits”
 - 153 drugs, vaccines, biologics and *in vivo* diagnostics* approved by FDA
 - 1985 - 2009
 - Northwestern monetized its Lyrica royalties December 2007
 - 50% interest
 - \$700 million
 - Only 198 licenses generated over \$1 million in income in 2008
 - Out of 15,498 generating some sort of income
 - 1.3%

* Source: Stevens, Jensen, Wyller, Chatterjee, London and Rohrbaugh, forthcoming



Was Bayh-Dole an Unfunded Mandate?

- Supplied no new funding
- Intended to be funded through IDC
 - Then we got the 26% administrative cap!
 - Much longer timeline to sustainability from income than expected
 - And patents expire!



One Man's Proposal

- Entrepreneurial Postdoctoral Fellowships
 - For graduating Ph.D. students or current postdocs
 - Commercialize the science they're working on
 - Statewide selection
 - Competitive peer review
 - Two years support
 - Proof-of-concept scientific experiments
 - Business plan development
 - Business school for entrepreneurial education
 - Mentorship program